Bristol-Myers Squibb Beats Q2 Expectations, Boosts Guidance on Rising Drug Sales

Key TakeawaysBristol-Myers Squibb's second-quarter results beat revenue and adjusted EPS expectations.The company raised its full-year adjusted EPS guidance and now projects adjusted revenue to land in the upper end of its previously issued range.Revenue growth was driven by sales of its blood thinner Eliquis and cancer drug Opdivo. Bristol-Myers Squibb (BMY) shares climbed Friday after the company beat expectations with its second-quarter results and raised its full-year guidance. The pharmaceutical giant ...